Adjuvant therapy for renal cell carcinoma: past, present, and future
about
Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveMedical treatment of renal cancer: new horizonsHistological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomyProspective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial designAdjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor TherapyAdjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.Kidney cancer and 2014: is innovation really over?Role of targeted therapy in combination with surgery in renal cell carcinoma.Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI.Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models.ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study.Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.Treatment of renal cell carcinoma: Current status and future directions.The current status of adjuvant treatment for high-risk renal cell carcinoma.Cystic Duct Metastasis from Renal Cell Carcinoma.Renal cell carcinoma: An update for the practicing urologist.Metastasis in renal cell carcinoma: Biology and implications for therapy.Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for TreatmentIs there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts
P2860
Q26744089-2BF49F1B-BB1A-40A3-9568-FF34E66AF390Q28073174-12D8AD99-794E-450F-AB6A-A2310E068856Q35947018-A7509FA5-1B89-4F4B-9AFB-583FA4299B62Q36078353-EA24CD25-FDD7-41EA-AA0B-EB9444E2C87DQ36932216-5BE983D3-02C0-47A7-AFAA-AD2AF3A762BDQ37117930-130A24C4-4ABE-4FFA-BFB6-04E221898A07Q38379672-D3956C16-E386-4AD3-BB45-C68A85B302D8Q38385722-B92795AC-E4E7-43F7-951E-58FDF998ED24Q38465870-365A3ECA-4808-4292-A3C1-E4F217B49628Q38560110-49E9ED73-D975-40BB-8ED6-B2CC55B27623Q38586999-E3803E88-9121-4485-B83F-26584B0E4A5DQ41252294-BD1F9218-8056-4D08-B66F-AFB20EEB4244Q41472778-B44BA548-C3A6-480C-BF3C-B501F06C992AQ42370353-0D1117F3-AD1B-4B55-BBCE-E1CC28CD598BQ42379684-B421CE26-04C8-4613-8FC8-A81E0ABFC843Q47261072-7BE33617-442A-45C5-8B50-47CA0A8A6AAAQ47726014-83ADD3CA-62A6-475C-85E5-B5D19FF32B3BQ47912370-433D594F-6109-4971-A722-F270A5ADDA28Q50150067-71A6E31F-0F92-4487-B6D1-E788CF19AB28Q53649433-88CA06FB-1F75-4D45-ABA7-7539A6506528Q54936635-BB7CB733-DAAE-4688-A2DF-7BCB3DD2599EQ58796432-8DC9BA8E-64B6-4097-B137-2BB47333F64AQ59126184-E6171D4D-A8BC-4562-9CB1-1612EADC29CE
P2860
Adjuvant therapy for renal cell carcinoma: past, present, and future
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Adjuvant therapy for renal cell carcinoma: past, present, and future
@ast
Adjuvant therapy for renal cell carcinoma: past, present, and future
@en
Adjuvant therapy for renal cell carcinoma: past, present, and future
@nl
type
label
Adjuvant therapy for renal cell carcinoma: past, present, and future
@ast
Adjuvant therapy for renal cell carcinoma: past, present, and future
@en
Adjuvant therapy for renal cell carcinoma: past, present, and future
@nl
prefLabel
Adjuvant therapy for renal cell carcinoma: past, present, and future
@ast
Adjuvant therapy for renal cell carcinoma: past, present, and future
@en
Adjuvant therapy for renal cell carcinoma: past, present, and future
@nl
P2860
P1433
P1476
Adjuvant therapy for renal cell carcinoma: past, present, and future
@en
P2093
Naomi B Haas
Sumanta K Pal
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0105
P577
2014-06-26T00:00:00Z